By Michele Maatouk
Date: Tuesday 07 Apr 2026
(Sharecast News) - California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.
| Currency | US Dollars |
| Share Price | $ 130.52 |
| Change Today | $ 1.21 |
| % Change | 0.94 % |
| 52 Week High | $155.80 |
| 52 Week Low | $110.50 |
| Volume | 4,953,801 |
| Shares Issued | 1,241.00m |
| Market Cap | $161,975m |
| Beta | 0.01 |
| RiskGrade | 120 |
| Time | Volume / Share Price |
| 15:59 | 1,630 @ $130.49 |
| 15:59 | 6,100 @ $130.49 |
| 15:59 | 6,100 @ $130.49 |
| 15:59 | 816 @ $130.49 |
| 15:59 | 1,000 @ $130.49 |
You are here: research